Evidence map›Paper›PMID 31506829›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2020

New multifunctional AChE inhibitor drug prototypes protect against Aβ-induced memory deficit.

Paula M Q Bellozi, Alline C Campos, Flávia P D Viegas, Matheus de F Silva, Rafael P Machado, Sarah M Vaz, Mariana M Riquiel, Wellerson de O Carneiro-Junior, Isabel V de A Lima, Soraya W Saliba and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Paula M Q BelloziInstitute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, 31270-901, Brazil.
Alline C CamposDepartment of Pharmacology, Federal University of de São Paulo, Ribeirão Preto, SP, 14049-900, Brazil.
Flávia P D ViegasInstitute of Chemistry, Laboratory of Research on Medicinal Chemistry, Federal University of Alfenas, Alfenas, MG, 37133-840, Brazil.
Matheus de F SilvaInstitute of Chemistry, Laboratory of Research on Medicinal Chemistry, Federal University of Alfenas, Alfenas, MG, 37133-840, Brazil.
Rafael P MachadoInstitute of Chemistry, Laboratory of Research on Medicinal Chemistry, Federal University of Alfenas, Alfenas, MG, 37133-840, Brazil.
Sarah M VazInstitute of Chemistry, Laboratory of Research on Medicinal Chemistry, Federal University of Alfenas, Alfenas, MG, 37133-840, Brazil.
Mariana M RiquielInstitute of Chemistry, Laboratory of Research on Medicinal Chemistry, Federal University of Alfenas, Alfenas, MG, 37133-840, Brazil.
Wellerson de O Carneiro-JuniorInstitute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, 31270-901, Brazil.
Isabel V de A LimaInstitute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, 31270-901, Brazil.
Soraya W SalibaInstitute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, 31270-901, Brazil.
Gabriela Neves VazInstitute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, 31270-901, Brazil.
Claudio ViegasInstitute of Chemistry, Laboratory of Research on Medicinal Chemistry, Federal University of Alfenas, Alfenas, MG, 37133-840, Brazil. cvjviegas@gmail.com.
Antônio C P de OliveiraInstitute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, MG, 31270-901, Brazil. antoniooliveira@icb.ufmg.br.ORCID http://orcid.org/0000-0003-3217-4294
Universidade Federal de Alfenas · BRUniversidade Federal de Minas Gerais · BRUniversidade Federal de São Paulo · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 400271/2014-1Conselho Nacional de Desenvolvimento Científico e Tecnológico 406739/2018-8Conselho Nacional de Desenvolvimento Científico e Tecnológico 424588/2016-1Conselho Nacional de Desenvolvimento Científico e Tecnológico 454088/2014-0Fundação de Amparo à Pesquisa do Estado de Minas Gerais CBB - APQ-02044-15Fundação de Amparo à Pesquisa do Estado de Minas Gerais CEX-PPM-00241-15
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most incident neurodegenerative disorder, characterized by accumulation of extracellular amyloid-β (Aβ), intracellular neurofibrillary tangles, and cognitive impairment. The current available treatments are mainly based on the use of reversible acetylcholinesterase (AChE) inhibitors, which only ameliorate the cognitive deficits. However, it is important to develop disease-modifying drugs with neuroprotective effects in order to hamper the progression of the disease. Here, we describe the effect of four promising new drugs with additional protective characteristics on AD-associated memory changes. C57Bl/6 mice treated with the compounds received an intra-hippocampal injection of Aβ1-40 and were submitted to the novel object recognition test, to evaluate memory recovery. All the compounds prevented memory loss. Compounds PQM-56 (4c) and PQM-67 (4g) showed the best profile of memory recovery, representing potential drug candidates for AD treatment.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsCholinesterase InhibitorsCognition DisordersDisease Models, AnimalMemoryMemory DisordersMice, Inbred C57BLNeuroprotective AgentsPeptide FragmentsAmyloid beta-PeptidesCholinesterase InhibitorsNeuroprotective AgentsPeptide FragmentsAlzheimer’s diseaseAmyloid-βMemoryN-benzyl-piperidine-aryl-acylhydrazone derivatives

Identifiers

PMID31506829
OpenAlexW2972701841

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.